The new system removes the requirement for providers to draw individual syringes of hyaluronic acid.
LRM Aesthetics Inc announced the Syringe2Syringe configuration for ariessence pure PDGF+, a topical post-procedural enhancement. The new packaging model is designed to support provider efficiency and precision in aesthetic practices.
The topical consists of recombinant, sterile platelet-derived growth factor combined with sterile hyaluronic acid. It is intended to complement professional aesthetic care and can be used following procedures such as microneedling, radiofrequency microneedling, laser skin resurfacing, and peels, according to a company press release.
“ariessence pure PDGF+ was developed to provide aesthetic professionals with a scientifically advanced topical formulation designed to complement in-office aesthetic treatments,” says Samuel Lynch, founder and CEO of LRM, in a release. “The new Syringe2Syringe configuration reflects our continued commitment to innovation by simplifying preparation and helping providers integrate ariessence pure PDGF+ more seamlessly into clinical workflows.”
Streamlining Clinical Workflows
The new system removes the requirement for providers to draw individual syringes of hyaluronic acid. The all-in-one system requires no additional components and features a blend-ready design for preparation. Each sterile pack is intended for single-patient use, which allows the platelet-derived growth factor and hyaluronic acid to be mixed while supporting treatment consistency.
Each Syringe2Syringe package includes five syringes containing 0.5 ml of pure platelet-derived growth factor, five syringes containing 1.5 ml of pure hyaluronic acid, and five sterile mixing tips. The company states that the configuration also reduces the packaging footprint by utilizing 100% recyclable carton components.
“The Syringe2Syringe system makes a meaningful difference in clinical practice because it further streamlines preparation while helping ensure consistency from one treatment to the next,” says Dr Terrence Keaney, a dermatologist, in a release. “By eliminating extra preparation steps and providing a ready-to-mix format, it allows providers to focus more on the patient experience, procedural efficiency, and faster preparation while maintaining confidence in precise application.”
Formulation and Manufacturing
The ariessence pure PDGF+ formulation contains four ingredients: water, sodium acetate, hyaluronic acid, and platelet-derived growth factor. The product is manufactured under controlled quality standards to provide a consistent topical option for aesthetic providers.
LRM Aesthetics, Inc is a subsidiary of Lynch Regenerative Medicine, LLC, a commercial-stage biotech company based in Franklin, Tennessee. The company develops recombinant growth factor products for therapeutic indications and cosmetic applications, including treatments for chronic wounds and periodontal regeneration.
Photo caption: The new Syringe2Syringe configuration for ariessence pure PDGF+
Photo credit: LRM Aesthetics
